Protection against retroviral diseases after vaccination is conferred by interference to superinfection with attenuated murine leukemia viruses.
Cell cultures expressing a retroviral envelope are relatively resistant to superinfection by retroviruses which bear envelopes using the same receptor. We tested whether this phenomenon, known as interference to superinfection, might confer protection against retroviral diseases. Newborn mice first inoculated with the attenuated strain B3 of Friend murine leukemia virus (F-MuLV) were protected against severe early hemolytic anemia and nonacute anemiant erythroleukemia induced by the virulent strain 57 of F-MuLV. Vaccinated animals were also protected as adults against acute polycythemic erythroleukemia induced upon inoculation with the viral complex containing the defective spleen focus-forming virus and F-MuLV 57 as helper virus. Animals were inoculated as newborns, which is known to induce immune tolerance in mice, and the rapid kinetics of protection, incompatible with the delay necessary for the immune response to develop, indicated that protection was not due to an immune mechanism but rather was due to the rapid and long-lasting phenomenon of interference. This result was confirmed by combining parental and envelope chimeric MuLV from different interference groups as vaccinal and challenge viruses. Although efficient protection could be provided by vaccination by interference, we observed that attenuated replication-competent retroviruses from heterologous interference groups might exert deleterious synergistic effects.
Corbin
A
A
Laboratoire d'Oncologie Cellulaire et Moléculaire, Unité INSERM 363, Institut Cochin de Génétique Moléculaire, Université Paris V, France.
Sitbon
M
M
D000375:Aging / Q000276:immunology; D000818:Animals; D000831:Animals, Newborn; D002460:Cell Line; D005622:Friend murine leukemia virus / Q000276:immunology*; D007108:Immune Tolerance; D009052:Leukemia Virus, Murine / Q000276:immunology* / Q000472:pathogenicity; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology / Q000517:prevention & control; D007942:Leukemia, Experimental / Q000276:immunology* / Q000517:prevention & control; D051379:Mice; D008815:Mice, Inbred Strains; D012190:Retroviridae / Q000276:immunology*; D014412:Tumor Virus Infections / Q000276:immunology* / Q000517:prevention & control; D014613:Vaccines, Attenuated / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000627:therapeutic use*
D014613:Vaccines, Attenuated; D014765:Viral Vaccines